FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic in U.S. Market
Key Insights
Novo Nordisk has identified several hundred units of counterfeit Ozempic 1 mg injections circulating outside the authorized supply chain in the United States.
The counterfeit products feature authentic lot number PAR0362 combined with illegitimate serial numbers beginning with digits 51746517, which may pose significant safety risks to patients.
Health authorities cannot confirm the contents or quality of the seized counterfeits, which include potentially non-sterile needles that could cause infections.
Pharmaceutical giant Novo Nordisk and the U.S. Food and Drug Administration (FDA) have issued urgent warnings about counterfeit versions of the popular diabetes (search) and weight loss medication Ozempic circulating in the American market.
The Danish drugmaker has identified several hundred units of counterfeit Ozempic injection 1 mg that have been distributed outside Novo Nordisk's authorized supply chain in the United States. These fake products could pose significant health risks to unsuspecting patients.
How to Identify the Counterfeits
The seized counterfeit products bear a specific combination of identifiers that consumers and healthcare providers should immediately check for. They feature the authentic lot number PAR0362 paired with illegitimate serial numbers that begin with the first eight digits 51746517.
"Lot number PAR0362 is an authentic lot number. Only when both the lot number is coupled with the eight digits 51746517, is it counterfeit and should not be used," Novo Nordisk clarified in their announcement.
The FDA has updated its website with detailed information about these counterfeit versions to help protect consumers.
Unknown Contents Pose Safety Risks
Both Novo Nordisk and the FDA have expressed serious concerns about the potential dangers of these counterfeit products. As the investigation continues, extensive visual examination and chemical testing of the seized products are underway.
"Neither Novo Nordisk nor FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product," the company stated.
The FDA's investigation has revealed additional concerns about the counterfeit needles included with these fake Ozempic pens. These needles have not been certified as sterile, potentially exposing users to serious infection risks.
Supply Chain Security Measures
In response to this threat, Novo Nordisk is urging pharmacies and individuals to purchase Ozempic (semaglutide) injection 1 mg and other semaglutide-containing medicines exclusively through authorized distributors of Novo Nordisk.
This incident comes amid ongoing global shortages of Ozempic and related GLP-1 (search) receptor agonist medications, which have seen surging demand for both diabetes (search) management and off-label weight loss use. The supply constraints have created market conditions that counterfeiters are attempting to exploit.
Patient Recommendations
Patients currently using Ozempic are advised to:
- Immediately check their Ozempic packaging for the combination of lot number PAR0362 and serial numbers beginning with 51746517
- Discontinue use of any products identified as counterfeit
- Report suspicious products to the FDA and Novo Nordisk
- Consult with healthcare providers about obtaining legitimate replacement medication
Healthcare providers are being encouraged to verify the authenticity of Ozempic products before prescribing or administering them to patients, particularly those sourced outside of established supply chains.
The investigation into the source and distribution channels of these counterfeit products remains ongoing, with both Novo Nordisk and regulatory authorities working to prevent further circulation of potentially dangerous fake medications.